{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:00:00Z","timestamp":1791673200879,"version":"4.3.4"},"reference-count":77,"publisher":"e-Century Publishing Corporation","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Cancer Res"],"DOI":"10.62347\/ovuj4436","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T23:15:45Z","timestamp":1743117345000},"page":"1248-1263","source":"Crossref","is-referenced-by-count":5,"title":["Tissue inhibitor of metalloproteinase 1 as a biomarker of venous invasion in pancreatic ductal adenocarcinoma"],"prefix":"10.62347","volume":"15","author":[{"given":"You-Na","family":"Sung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"48694","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Kang MJ, Jung KW, Bang SH, Choi SH, Park EH, Yun EH, Kim HJ, Kong HJ, Im JS and Seo HG; Community of Population-Based Regional Cancer Registries*. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2020. Cancer Res Treat 2023; 55: 385-399.","DOI":"10.4143\/crt.2023.447"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Jung KW, Kang MJ, Park EH, Yun EH, Kim HJ, Kong HJ, Im JS and Seo HG. Prediction of cancer incidence and mortality in Korea, 2023. Cancer Res Treat 2023; 55: 400-407.","DOI":"10.4143\/crt.2023.448"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Wagle NS and Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73: 17-48.","DOI":"10.3322\/caac.21763"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH and Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4: 567-579.","DOI":"10.1016\/S1091-255X(00)80105-5"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM and Farnell MB. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 2008; 247: 456-462.","DOI":"10.1097\/SLA.0b013e3181613142"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"House MG, Gonen M, Jarnagin WR, D’Angelica M, DeMatteo RP, Fong Y, Brennan MF and Allen PJ. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007; 11: 1549-1555.","DOI":"10.1007\/s11605-007-0243-7"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lim JE, Chien MW and Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003; 237: 74-85.","DOI":"10.1097\/00000658-200301000-00011"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Nakao A, Harada A, Nonami T, Kaneko T and Takagi H. Clinical significance of carcinoma invasion of the extrapancreatic nerve plexus in pancreatic cancer. Pancreas 1996; 12: 357-361.","DOI":"10.1097\/00006676-199605000-00006"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Strobel O, Hank T, Hinz U, Bergmann F, Schneider L, Springfeld C, Jager D, Schirmacher P, Hackert T and Buchler MW. Pancreatic cancer surgery: the new R-status counts. Ann Surg 2017; 265: 565-573.","DOI":"10.1097\/SLA.0000000000001731"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Wang J, Lyu SC, Zhou L, Wang H, Pan F, Jiang T, Lang R and He Q. Prognostic analysis of pancreatic carcinoma with portal system invasion following curative resection. Gland Surg 2021; 10: 35-49.","DOI":"10.21037\/gs-20-495"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Fukuda S, Oussoultzoglou E, Bachellier P, Rosso E, Nakano H, Audet M and Jaeck D. Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma. Arch Surg 2007; 142: 172-179; discussion 180.","DOI":"10.1001\/archsurg.142.2.172"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Wang J, Estrella JS, Peng L, Rashid A, Varadhachary GR, Wang H, Lee JE, Pisters PW, Vauthey JN, Katz MH, Gomez HF, Evans DB, Abbruzzese JL, Fleming JB and Wang H. Histologic tumor involvement of superior mesenteric vein\/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation. Cancer 2012; 118: 3801-3811.","DOI":"10.1002\/cncr.26717"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Hruban RH, Gaida MM, Thompson E, Hong SM, Noe M, Brosens LA, Jongepier M, Offerhaus GJA and Wood LD. Why is pancreatic cancer so deadly? The pathologist’s view. J Pathol 2019; 248: 131-141.","DOI":"10.1002\/path.5260"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Smith C, Zheng W, Dong J, Wang Y, Lai J, Liu X and Yin F. Tumor microenvironment in pancreatic ductal adenocarcinoma: implications in immunotherapy. World J Gastroenterol 2022; 28: 3297-3313.","DOI":"10.3748\/wjg.v28.i27.3297"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Luo W, Wen T and Qu X. Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept. J Exp Clin Cancer Res 2024; 43: 8.","DOI":"10.1186\/s13046-023-02935-3"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Hartupee C, Nagalo BM, Chabu CY, Tesfay MZ, Coleman-Barnett J, West JT and Moaven O. Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target. Front Immunol 2024; 15: 1287459.","DOI":"10.3389\/fimmu.2024.1287459"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Hong SM, Jung D, Kiemen A, Gaida MM, Yoshizawa T, Braxton AM, Noe M, Lionheart G, Oshima K, Thompson ED, Burkhart R, Wu PH, Wirtz D, Hruban RH and Wood LD. Three-dimensional visualization of cleared human pancreas cancer reveals that sustained epithelial-to-mesenchymal transition is not required for venous invasion. Mod Pathol 2020; 33: 639-647.","DOI":"10.1038\/s41379-019-0409-3"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Krishnan MS, Rajan Kd A, Park J, Arjunan V, Garcia Marques FJ, Bermudez A, Girvan OA, Hoang NS, Yin J, Nguyen MH, Kothary N, Pitteri S, Felsher DW and Dhanasekaran R. Genomic analysis of vascular invasion in HCC reveals molecular drivers and predictive biomarkers. Hepatology 2021; 73: 2342-2360.","DOI":"10.1002\/hep.31614"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Zhang R, Ye J, Huang H and Du X. Mining featured biomarkers associated with vascular invasion in HCC by bioinformatics analysis with TCGA RNA sequencing data. Biomed Pharmacother 2019; 118: 109274.","DOI":"10.1016\/j.biopha.2019.109274"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Mannelqvist M, Stefansson IM, Bredholt G, Hellem Bo T, Oyan AM, Jonassen I, Kalland KH, Salvesen HB and Akslen LA. Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer. Am J Pathol 2011; 178: 861-871.","DOI":"10.1016\/j.ajpath.2010.10.040"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Zhang L, Wang Z, Li M, Sun P, Bai T, Wang W, Bai H, Gou J and Wang Z. HCG18 participates in vascular invasion of hepatocellular carcinoma by regulating macrophages and tumor stem cells. Front Cell Dev Biol 2021; 9: 707073.","DOI":"10.3389\/fcell.2021.707073"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Aljohani AI, Toss MS, Green AR and Rakha EA. The clinical significance of cyclin B1 (CCNB1) in invasive breast cancer with emphasis on its contribution to lymphovascular invasion development. Breast Cancer Res Treat 2023; 198: 423-435.","DOI":"10.1007\/s10549-022-06801-2"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Jung D, Shin J, Park J, Shin J, Sung YN, Kim Y, Yoo S, Lee BW, Jang SW, Park IJ, Wood LD, Pack CG, Hruban RH and Hong SM. Frequent intraluminal growth of large muscular veins in surgically resected colorectal cancer tissues: a 3-dimensional pathologic reconstruction study. Mod Pathol 2023; 36: 100082.","DOI":"10.1016\/j.modpat.2022.100082"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Song T, Dou C, Jia Y, Tu K and Zheng X. TIMP-1 activated carcinoma-associated fibroblasts inhibit tumor apoptosis by activating SDF1\/CXCR4 signaling in hepatocellular carcinoma. Oncotarget 2015; 6: 12061-12079.","DOI":"10.18632\/oncotarget.3616"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Song G, Xu S, Zhang H, Wang Y, Xiao C, Jiang T, Wu L, Zhang T, Sun X, Zhong L, Zhou C, Wang Z, Peng Z, Chen J and Wang X. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K\/AKT and MAPK pathway. J Exp Clin Cancer Res 2016; 35: 148.","DOI":"10.1186\/s13046-016-0427-7"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Shou Y, Liu Y, Xu J, Liu J, Xu T, Tong J, Liu L, Hou Y, Liu D, Yang H, Cheng G and Zhang X. TIMP1 indicates poor prognosis of renal cell carcinoma and accelerates tumorigenesis via EMT signaling pathway. Front Genet 2022; 13: 648134.","DOI":"10.3389\/fgene.2022.648134"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Bodoque-Villar R, Padilla-Valverde D, Gonzalez-Lopez LM, Munoz-Rodriguez JR, Arias-Pardilla J, Villar-Rodriguez C, Gomez-Romero FJ, Verdugo-Moreno G, Redondo-Calvo FJ and Serrano-Oviedo L. The importance of CXCR4 expression in tumor stroma as a potential biomarker in pancreatic cancer. World J Surg Oncol 2023; 21: 287.","DOI":"10.1186\/s12957-023-03168-6"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Na IK, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E, Keilholz U and Coupland SE. Nuclear expression of CXCR4 in tumor cells of non-small cell lung cancer is correlated with lymph node metastasis. Hum Pathol 2008; 39: 1751-1755.","DOI":"10.1016\/j.humpath.2008.04.017"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Wang P, Yang X, Zhou N, Wang J, Li Y, Liu Y, Xu X and Wei W. Identifying a potential key gene, TIMP1, associated with liver metastases of uveal melanoma by weight gene co-expression network analysis. Onco Targets Ther 2020; 13: 11923-11934.","DOI":"10.2147\/OTT.S280435"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Huang R, Wang K, Gao L and Gao W. TIMP1 is a potential key gene associated with the pathogenesis and prognosis of ulcerative colitis-associated colorectal cancer. Onco Targets Ther 2019; 12: 8895-8904.","DOI":"10.2147\/OTT.S222608"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Wurtz SO, Schrohl AS, Mouridsen H and Brunner N. TIMP-1 as a tumor marker in breast cancer--an update. Acta Oncol 2008; 47: 580-590.","DOI":"10.1080\/02841860802022976"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brunner N and Foekens JA. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004; 10: 2289-2298.","DOI":"10.1158\/1078-0432.CCR-03-0360"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Nakopoulou L, Giannopoulou I, Stefanaki K, Panayotopoulou E, Tsirmpa I, Alexandrou P, Mavrommatis J, Katsarou S and Davaris P. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis. J Pathol 2002; 197: 307-313.","DOI":"10.1002\/path.1129"},{"key":"ref33","unstructured":"Lee JH, Choi JW and Kim YS. Plasma or serum TIMP-1 is a predictor of survival outcomes in colorectal cancer: a meta-analysis. J Gastrointestin Liver Dis 2011; 20: 287-291."},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Wang YY, Li L, Zhao ZS and Wang HJ. Clinical utility of measuring expression levels of KAP1, TIMP1 and STC2 in peripheral blood of patients with gastric cancer. World J Surg Oncol 2013; 11: 81.","DOI":"10.1186\/1477-7819-11-81"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Liu H, Xiang Y, Zong QB, Zhang XY, Wang ZW, Fang SQ, Zhang TC and Liao XH. miR-6745-TIMP1 axis inhibits cell growth and metastasis in gastric cancer. Aging (Albany NY) 2021; 13: 24402-24416.","DOI":"10.18632\/aging.203688"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Grunnet M, Mau-Sorensen M and Brunner N. Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scand J Gastroenterol 2013; 48: 899-905.","DOI":"10.3109\/00365521.2013.812235"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Creme E, Wurtz A, Porte H and Huet G. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent. Cancer 2005; 103: 1676-1684.","DOI":"10.1002\/cncr.20965"},{"key":"ref38","unstructured":"Fong KM, Kida Y, Zimmerman PV and Smith PJ. TIMP1 and adverse prognosis in non-small cell lung cancer. Clin Cancer Res 1996; 2: 1369-1372."},{"key":"ref39","unstructured":"Honkavuori M, Talvensaari-Mattila A, Puistola U, Turpeenniemi-Hujanen T and Santala M. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma. Anticancer Res 2008; 28: 2715-2719."},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, Jurkowska G and Szmitkowski M. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009; 38: 613-618.","DOI":"10.1097\/MPA.0b013e3181a488a0"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Schoeps B, Eckfeld C, Prokopchuk O, Bottcher J, Haussler D, Steiger K, Demir IE, Knolle P, Soehnlein O, Jenne DE, Hermann CD and Kruger A. TIMP1 triggers neutrophil extracellular trap formation in pancreatic cancer. Cancer Res 2021; 81: 3568-3579.","DOI":"10.1158\/0008-5472.CAN-20-4125"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Tian Z, Ou G, Su M, Li R, Pan L, Lin X, Zou J, Chen S, Li Y, Huang K and Chen Y. TIMP1 derived from pancreatic cancer cells stimulates Schwann cells and promotes the occurrence of perineural invasion. Cancer Lett 2022; 546: 215863.","DOI":"10.1016\/j.canlet.2022.215863"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Toricelli M, Melo FHM, Hunger A, Zanatta D, Strauss BE and Jasiulionis MG. Timp1 promotes cell survival by activating the PDK1 signaling pathway in melanoma. Cancers (Basel) 2017; 9: 37.","DOI":"10.3390\/cancers9040037"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Wojtowicz-Praga SM, Dickson RB and Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15: 61-75.","DOI":"10.1023\/A:1005722729132"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Cruz-Munoz W and Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008; 45: 291-338.","DOI":"10.1080\/10408360801973244"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Moore CS and Crocker SJ. An alternate perspective on the roles of TIMPs and MMPs in pathology. Am J Pathol 2012; 180: 12-16.","DOI":"10.1016\/j.ajpath.2011.09.008"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Jung KK, Liu XW, Chirco R, Fridman R and Kim HR. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006; 25: 3934-3942.","DOI":"10.1038\/sj.emboj.7601281"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"D’Angelo RC, Liu XW, Najy AJ, Jung YS, Won J, Chai KX, Fridman R and Kim HR. TIMP-1 via TWIST1 induces EMT phenotypes in human breast epithelial cells. Mol Cancer Res 2014; 12: 1324-1333.","DOI":"10.1158\/1541-7786.MCR-14-0105"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Justo BL and Jasiulionis MG. Characteristics of TIMP1, CD63, and beta1-integrin and the functional impact of their interaction in cancer. Int J Mol Sci 2021; 22: 9319.","DOI":"10.3390\/ijms22179319"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"Gonzalez LO, Eiro N, Fraile M, Sanchez R, Andicoechea A, Fernandez-Francos S, Schneider J and Vizoso FJ. Joint tumor Bud-MMP\/TIMP count at the invasive front improves the prognostic evaluation of invasive breast carcinoma. Biomedicines 2021; 9: 196.","DOI":"10.3390\/biomedicines9020196"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Seubert B, Grunwald B, Kobuch J, Cui H, Schelter F, Schaten S, Siveke JT, Lim NH, Nagase H, Simonavicius N, Heikenwalder M, Reinheckel T, Sleeman JP, Janssen KP, Knolle PA and Kruger A. Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1\/CXCR4-dependent neutrophil recruitment in mice. Hepatology 2015; 61: 238-248.","DOI":"10.1002\/hep.27378"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Rao VS, Gu Q, Tzschentke S, Lin K, Ganig N, Thepkaysone ML, Wong FC, Polster H, Seifert L, Seifert AM, Buck N, Riediger C, Weisse J, Gutschner T, Michen S, Temme A, Schneider M, Baenke F, Weitz J and Kahlert C. Extravesicular TIMP-1 is a non-invasive independent prognostic marker and potential therapeutic target in colorectal liver metastases. Oncogene 2022; 41: 1809-1820.","DOI":"10.1038\/s41388-022-02218-9"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM and Mulvihill SJ. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas 2013; 42: 193-197.","DOI":"10.1097\/MPA.0b013e31825e354d"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Grunwald B, Harant V, Schaten S, Fruhschutz M, Spallek R, Hochst B, Stutzer K, Berchtold S, Erkan M, Prokopchuk O, Martignoni M, Esposito I, Heikenwalder M, Gupta A, Siveke J, Saftig P, Knolle P, Wohlleber D and Kruger A. Pancreatic premalignant lesions secrete tissue inhibitor of metalloproteinases-1, which activates hepatic stellate cells via CD63 signaling to create a premetastatic niche in the liver. Gastroenterology 2016; 151: 1011-1024, e1017.","DOI":"10.1053\/j.gastro.2016.07.043"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"D’Costa Z, Jones K, Azad A, van Stiphout R, Lim SY, Gomes AL, Kinchesh P, Smart SC, Gillies McKenna W, Buffa FM, Sansom OJ, Muschel RJ, O’Neill E and Fokas E. Gemcitabine-Induced TIMP1 attenuates therapy response and promotes tumor growth and liver metastasis in pancreatic cancer. Cancer Res 2017; 77: 5952-5962.","DOI":"10.1158\/0008-5472.CAN-16-2833"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Bloomston M, Shafii A, Zervos E and Rosemurgy AS. TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo. Am J Surg 2005; 189: 675-679.","DOI":"10.1016\/j.amjsurg.2005.03.008"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Zhang J, Wang J, Yue K, Li P, Shen W, Qiao X, Wang Y and Wu X. FAM83B promotes the invasion of primary lung adenocarcinoma via PI3K\/AKT\/NF-kappaB pathway. BMC Pulm Med 2023; 23: 32.","DOI":"10.1186\/s12890-022-02303-5"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Wang L, Wang J and Chen L. TIMP1 represses sorafenib-triggered ferroptosis in colorectal cancer cells by activating the PI3K\/Akt signaling pathway. Immunopharmacol Immunotoxicol 2023; 45: 419-425.","DOI":"10.1080\/08923973.2022.2160731"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Tian Z, Tan Y, Lin X, Su M, Pan L, Lin L, Ou G and Chen Y. Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1\/PI3K\/AKT\/mTOR axis. Transl Res 2023; 255: 66-76.","DOI":"10.1016\/j.trsl.2022.11.007"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Su Y, Wan D and Song W. Dryofragin inhibits the migration and invasion of human osteosarcoma U2OS cells by suppressing MMP-2\/9 and elevating TIMP-1\/2 through PI3K\/AKT and p38 MAPK signaling pathways. Anticancer Drugs 2016; 27: 660-668.","DOI":"10.1097\/CAD.0000000000000381"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Jung YS, Liu XW, Chirco R, Warner RB, Fridman R and Kim HR. TIMP-1 induces an EMT-like phenotypic conversion in MDCK cells independent of its MMP-inhibitory domain. PLoS One 2012; 7: e38773.","DOI":"10.1371\/journal.pone.0038773"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Kwa MQ, Herum KM and Brakebusch C. Cancer-associated fibroblasts: how do they contribute to metastasis? Clin Exp Metastasis 2019; 36: 71-86.","DOI":"10.1007\/s10585-019-09959-0"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Joshi RS, Kanugula SS, Sudhir S, Pereira MP, Jain S and Aghi MK. The role of cancer-associated fibroblasts in tumor progression. Cancers (Basel) 2021; 13: 1399.","DOI":"10.3390\/cancers13061399"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Asif PJ, Longobardi C, Hahne M and Medema JP. The role of cancer-associated fibroblasts in cancer invasion and metastasis. Cancers (Basel) 2021; 13: 4720.","DOI":"10.3390\/cancers13184720"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Singh S, Singh AP and Mitra R. Cancer-associated fibroblasts: major co-conspirators in tumor development. Cancers (Basel) 2024; 16: 211.","DOI":"10.3390\/cancers16010211"},{"key":"ref66","doi-asserted-by":"publisher","unstructured":"Pape J, Magdeldin T, Stamati K, Nyga A, Loizidou M, Emberton M and Cheema U. Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma. Br J Cancer 2020; 123: 1178-1190.","DOI":"10.1038\/s41416-020-0973-9"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Nakai N, Hara M, Takahashi H, Shiga K, Hirokawa T, Maeda Y, Yanagita T, Ando N, Takasu K, Suzuki T, Maeda A, Ogawa R, Matsuo Y and Takiguchi S. Cancer cell‑induced tissue inhibitor of metalloproteinase‑1 secretion by cancer‑associated fibroblasts promotes cancer cell migration. Oncol Rep 2022; 47: 112.","DOI":"10.3892\/or.2022.8323"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Lu Y, Liu S, Zhang S, Cai G, Jiang H, Su H, Li X, Hong Q, Zhang X and Chen X. Tissue inhibitor of metalloproteinase-1 promotes NIH3T3 fibroblast proliferation by activating p-Akt and cell cycle progression. Mol Cells 2011; 31: 225-230.","DOI":"10.1007\/s10059-011-0023-9"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Gong Y, Scott E, Lu R, Xu Y, Oh WK and Yu Q. TIMP-1 promotes accumulation of cancer associated fibroblasts and cancer progression. PLoS One 2013; 8: e77366.","DOI":"10.1371\/journal.pone.0077366"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Mei XY, Zhang JN, Jia WY, Lu B, Wang MN, Zhang TY and Ji LL. Scutellarin suppresses triple-negative breast cancer metastasis by inhibiting TNFalpha-induced vascular endothelial barrier breakdown. Acta Pharmacol Sin 2022; 43: 2666-2677.","DOI":"10.1038\/s41401-022-00873-y"},{"key":"ref71","doi-asserted-by":"publisher","unstructured":"Gunduz D, Troidl C, Tanislav C, Rohrbach S, Hamm C and Aslam M. Role of PI3K\/Akt and MEK\/ERK signalling in cAMP\/Epac-mediated endothelial barrier stabilisation. Front Physiol 2019; 10: 1387.","DOI":"10.3389\/fphys.2019.01387"},{"key":"ref72","doi-asserted-by":"publisher","unstructured":"Peng Z, Pang H, Wu H, Peng X, Tan Q, Lin S and Wei B. CCL2 promotes proliferation, migration and angiogenesis through the MAPK\/ERK1\/2\/MMP9, PI3K\/AKT, Wnt\/beta‑catenin signaling pathways in HUVECs. Exp Ther Med 2022; 25: 77.","DOI":"10.3892\/etm.2022.11776"},{"key":"ref73","doi-asserted-by":"publisher","unstructured":"Cheng HW, Chen YF, Wong JM, Weng CW, Chen HY, Yu SL, Chen HW, Yuan A and Chen JJ. Cancer cells increase endothelial cell tube formation and survival by activating the PI3K\/Akt signalling pathway. J Exp Clin Cancer Res 2017; 36: 27.","DOI":"10.1186\/s13046-017-0495-3"},{"key":"ref74","doi-asserted-by":"publisher","unstructured":"Sleightholm RL, Neilsen BK, Li J, Steele MM, Singh RK, Hollingsworth MA and Oupicky D. Emerging roles of the CXCL12\/CXCR4 axis in pancreatic cancer progression and therapy. Pharmacol Ther 2017; 179: 158-170.","DOI":"10.1016\/j.pharmthera.2017.05.012"},{"key":"ref75","doi-asserted-by":"publisher","unstructured":"Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"ref76","unstructured":"Wang Z, Ma Q, Li P, Sha H, Li X and Xu J. Aberrant expression of CXCR4 and beta-catenin in pancreatic cancer. Anticancer Res 2013; 33: 4103-4110."}],"container-title":["American Journal of Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/3\/ajcr0161551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:50:51Z","timestamp":1766022651000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajcr\/15\/3\/ajcr0161551.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":77,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.62347\/ovuj4436","relation":{},"ISSN":["2156-6976"],"issn-type":[{"value":"2156-6976","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}